Inclusion Criteria:

          -  Metastatic disease not amenable to potentially curative surgery and with available
             archival tumor tissue or fresh tumor tissue biopsy.

          -  Presence of at least 1 measurable lesion assessed by CT and/or MRI according to RECIST
             1.1.

        For Cohort A:

        - First line metastatic colorectal cancer.

        For Cohort B:

        - Second line metastatic colorectal cancer that has progressed on prior chemotherapy
        administered for metastatic disease and which must include a fluoropyrimidine and
        oxaliplatin.

        For Cohort C:

        - Second line metastatic gastroesophageal cancer that has progressed on prior line of
        chemotherapy administered for metastatic disease, and which must include a platinum agent
        and fluoropyrimidine doublet.

        For Cohort D:

        - Second or third line metastatic renal cell carcinoma with a clear-cell component and has
        received one or two lines of treatment for metastatic disease that included an
        anti-angiogenic agent for at least 4 weeks with radiologic progression on that treatment.

        For subjects starting from Part 1a in Cohorts A and B:

          -  Serum hs-CRP at screening ≥ 10 mg/L.

          -  Not requiring immediate initiation of anti-cancer therapy per investigator's best
             judgement.

        For subjects starting from Part 2 in Cohorts C and D:

        - Serum hs-CRP at screening ≥ 10 mg/L.

        Exclusion Criteria:

        For All Cohorts:

          -  Currently receiving any of the prohibited medications or has contraindications as
             outlined in the protocol.

          -  Symptomatic brain metastases or brain metastases that require directed therapy (such
             as focal radiotherapy or surgery).

          -  Suspected or proven immunocompromised state, or infections (as defined in the
             protocol).

          -  Conditions that have a high risk of clinically significant bleeding after
             administration of anti-VEGF agents.

          -  Clinically significant, uncontrolled or recent (within last 6 months) cardiovascular
             disease.

        For Cohort D:

          -  Concomitant medications, herbal supplements, and/or fruits and their juices that are
             known as strong inhibitors or inducers of CYP3A4/5, and medications that have a narrow
             therapeutic window and are predominantly metabolized through CYP3A4/5.

          -  Impairment of GI function or GI disease that may significantly alter the absorption of
             cabozantinib.

        Other protocol-defined inclusion/exclusion criteria may apply